{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.1","value":"2400"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"title":"Platinum in plasma: Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"40.7","value":"636"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"title":"Platinum in plasma-ultrafiltrate: Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.3","value":"2420"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"title":"Platinum in plasma: Cycle 1 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.5","value":"697"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"title":"Platinum in plasma-ultrafiltrate: Cycle 1 Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Cmax was observed directly from data. Oxaliplatin was evaluated as total platinum in plasma and platinum in plasma ultrafiltrate.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received encorafenib 300 mg QD orally and cetuximab 500 mg/m\\^2 IV infusion for 120 minutes Q2W along with fluorouracil 400 mg/m\\^2 IV bolus then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W; leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and oxaliplatin 85 mg/m\\^2 IV infusion for 120 minutes Q2W. Participants received treatment in 28-day cycles.","id":"OG000","title":"SLI: Cohort 2 [EC + mFOLFOX6]"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK parameter analysis set was analyzed. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure. Here, \"Number Analyzed\" signifies participants evaluable at specified timepoints. Participants received oxaliplatin in Cohort 2 of SLI, hence data is reported only for Cohort 2 and not for Cohort 1.","reportingStatus":"POSTED","timeFrame":"Cohort 2: Pre-dose (0 hr), 1, 2, 3, 4, 6, 8, and 48 hrs post-dose on Days 1 and 15 of Cycle 1","title":"SLI, Cohort 2: Cmax of Oxaliplatin","type":"SECONDARY","unitOfMeasure":"Nanograms per milliliter"}